Linum usitatissimum commonly known as flax or linseed is an important medicinal plant, produces medicinally potent lignans, used in the treatment of several human diseases. Lignans limited production in the natural plants does not meet the increasing market demand. This study was conducted to establish an easy and rapid method for the in vitro micropropagation and production of potent lignans and antioxidant secondary metabolites in linseed. The results indicated that hypocotyl explants under the effects of thidiazuron (TDZ: 0.5 mg/L) + kinetin (Kn: 0.5 mg/L) in the basal growth media, resulted in the optimal shoot organogenesis parameters (shoot induction frequency: 86.87%, number of shoots: 6.3 ± 0.36 and shoots length: 6.5 ± 0.54 cm), in 4 weeks. Further, TDZ supplementation in the culture media efficiently activated the antioxidant system in the in vitro raised shoots, wherein maximum production of total phenolic content, TPC (34.33 ± 0.20 mg of GAE/g DW); total flavonoid content, TFC (8.99 ± 0.02 mg of QE/g DW); DPPH free radical scavenging activity (92.7 ± 1.32%); phenylalanine ammonia-lyase activity, PAL (8.99 ± 0.02 U/g FW); and superoxide dismutase expression, SOD (3.62 ± 0.01 nM/min/mg FW) were observed in the shoot cultures raised in presence of TDZ: 0.5 mg/L + Kn: 0.5 mg/L. Nonetheless, considerable levels of pharmacologically active lignans such as secoisolariciresinol (SECO: 23.13–37.10 mg/g DW), secoisolariciresinol diglucoside (SDG: 3.32–3.86 mg/g DW) and anhydrosecoisolariciresinol diglucoside (ANHSECO: 5.15–7.94 mg/g DW) were accumulated in the regenerated shoots. This protocol can be scaled up for the commercial production of linseed to meet the market demands for lignans.
The significant rise in the number of diabetic patients worldwide, as well as the development of new insulin delivery techniques such as inhalation or oral administration which require higher dosages, are expected to increase the demand for recombinant insulin. Current manufacturing technologies will be unable to fulfill the rising demand for inexpensive insulin due to their production capacity limitations and high production costs. Production of therapeutic recombinant insulin requires a suitable host organism with adequate post-translational modification and refolding machinery. E. coli and S. cerevisiae have been used extensively to make recombinant human insulin for medicinal applications. However, transgenic plants are particularly appealing expression systems as they can be used to synthesize huge amounts of insulin for human medicinal purposes. Plant-based expression systems have the potential for high-capacity insulin synthesis at a minimal cost. The significant production of biologically active proinsulin in seeds or leaves with long-term stability provides a low-cost technique to develop proinsulin for both injectable and oral administration. Recently, stem cell therapy is being utilized for the treatment of diabetes, as these cells are capable of differentiating into insulin producing c ells. With the advancement of regenerative medicine research for different chronic diseases, treatment for type 1 diabetes mellitus has been reported. The current review concentrates on several biotechnological attributes applied to the rapid and mass synthesis of biologically active insulin and its analogs in microbes, various types of stem cells and transgenic crops.
The universal emphasis on the study of green nanotechnology has led to biologically harmless uses of wide-ranged nanomaterials. Nanotechnology deals with the production of nanosized particles with regular morphology and properties. Various researches have been directed on nanomaterial synthesis by physical, chemical, and biological means. Understanding the safety of both environment and in vivo, a biogenic approach particularly plant-derived synthesis is the best strategy. Silver-zinc oxide nanoparticles are most effective. Moreover, these engineered nanomaterials via morphological modifications attain improved performance in antimicrobial, biomedical, environmental, and therapeutic applications. This article evaluates manufacturing strategies for silver-zinc oxide nanoparticles via plant-derived means along with highlighting their broad range of uses in bionanotechnology.
Stevia rebaudiana is a vital medicinal plant of the genus Stevia and family Asteraceae. It is
commonly used as a natural sweetener plant and its products are 300 times sweeter than the commonly
used sugarcane. The sweetening potential is due to the presence of calorie-free steviol glycosides
(SGs). The plant species has been extensively profiled to identify steviol glycosides (SGs) with intensity
sweetening properties. However, the limited production of plant material is not fulfilling the higher
market demand worldwide. Researchers are working worldwide to enhance the production of important
SGs through the intervention of different biotechnological approaches in S. rebaudiana. In this review,
the research work conducted in the last twenty years, on the different aspects of biotechnology to enhance
the production of SGs has been precisely reviewed. Biotechnological methods such as micropropagation,
callus and cell cultures, elicitation and the metabolomics and transcriptomic elucidation of
the biosynthetic metabolic pathways for the production of steviol glycosides have been concisely reviewed
and discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.